Gel cards and microplates for immunology and supplies

Institute of Transfusion Medicine

Part 1: Gel cards for ABO and Rh determination with monoclonal reagent and reversible grouping;
Part 2: Gel micro cards for set of interactions with monoclonal ABO/RhD confirmation and AHG testing;
Part 3: Gel micro cards for AHG screening of antibodies and interaction;
Part 4: Modified Bromelin solution for stabilized enzyme activity for preparation of suspensions from erythrocytes for blood grouping and enzyme testing, max 500 ml;
Part 5: Modified solution with a low iodine strength (LISS)for preparation of 5% suspensions from erythrocytes for blood grouping and enzyme testing, max 500 ml;
Part 6: Cell-reagent set for screening of antibodies in patents (I-II), set of 2 vials for IAT and Na Cl test;
Part 7: Cell reagent for screening of antibodies in blood donors (I-II), 2 pooled erythrocyte suspensions;
Part 8: Cell reagents for detection of presence or lack of anti-A and anti-B iso agglutinin in reversible grouping, A1-B;
Part 9: Gel cards for NaCl, enzyme test, cold agglutination;
Part 10: Gel micro cards for newborns with monoclonal antibodies ABO and RhD typing;
Part 11: Gel micro cards to determine the Du test, direct AHG test (DAT) and screening of antibodies, anti-IgG;
Part 12: Cell reagents containing cells appropriately selected to make sure the double presence of the significant blood group anti genes for identification of antibodies for IAT and Na CL test;
Part 13: Cell reagents providing identification of most anti genes and a mix of antigens in the Rh system for identification od anti bodies for enzyme testing, papainised;
Part 14: Cell reagents for 6 erythrocyte suspensions for screening of antibodies for IAT and enzyme test, papainised;
Part 15: Concentrated solution containing Glycin for Acid elution of serological antibodies;
Part 16: Gel micro cards for Rh phenotype + K antign;
Part 17: Gel micro card to confirm the blood type in a patient;
Part 18: Test monospecific direct AHG test IgG-IgA-IgM-C3e-C3d-etl;
Part 19: Means for decontamination based on benzalkonium chloride and tetra-anhydride EDTA (alkyldimethyl / ethyl / benzyl / ammonium chloride, tetrasodiumethylenediamine tetraacetate);
Part 20: Microplates with dry reagent for ABO and RhD determination and reversible grouping;
Part 21: Microplates with dry reagent for ABO and RhD determination;
Part 22: Microplates for dry reagent from mono clonal antibodies foer determining RH fenotype and K antigen;
Part 23: Cell reagent, 0,8% suspension for the determination of ABO antibodies to microwaves (set A1, B);
Part 24: Test for ID partial D typing;
Part 25: Test for typing of known partial D phenotypes, differentiation of weak D types of partial D;
Part 26: Complete blood and serum sets for quality control when working with gel cards (control of reagents, working procedures and instruments);
Part 27: Isotonic buffered rinsing solution, ready to use, max. 10 L;
Part 28: Rinsing solution ready for use max. 10 L;
Part 29: Concentrated rinsing solution;
Part 30: Solution of NaOH with concentration 0,5 m/l;
Part 31: Glass beads card for ABO and Rh determination with monoclonal reagent and reversible clustering;
Part 32: Card with glass beads for AHG screening of antibodies and inter reaction;
Part 33: A card with glass beads for confirmation of a blood group in a patient;
Part 34: A card with glass beads for neonates with monoclonal antibodies for ABO and Rh typing;
Part 35: Control qualitative reagent composed of full blood to confirm the accuracy of the results obtained in immuno hematological testing: ABO, Rh, AHG screening and interaction;
Part 36: LISS solution for enhancing the reaction between human erythrocytes and an antibody composed of a low ionic concentration;
Part 37: Reversible group cellular reagent composed of 3% suspension of A and B Rh negative human erythrocytes in a buffered phosphate-citrate solution;
Part 38: Cell reagent for screening of unexpected antibodies for an indirect anti-human globulin test composed of a 0,8% suspension of O Rh positive and Rh negative human erythrocytes in a LISS solution;
Part 39: Suspension consisting of a kit of two cells for the detection of unexpected antibodies (0.8% suspension);
Part 40: Cell reagent for the identification of unexpected antibodies for an indirect anti-human globulin test composed of a 0,8% suspension of O Rh positive and Rh negative human erythrocytes treated with enzyme fitsin in a LISS solution;
Part 41: Cell reagent for identification of unexpected antibodies for an indirect anti-human globulin test comprised of 0,8% suspension of O Rh positive and Rh negative human erythrocytes in LISS solution;
Part 42: Sodium hydroxide solution with a concentration of 0,1M / L;
Part 43: Flat microtiter plates (1 х 96), of polyvinyl chloride, translucent for the preparation of erythrocyte suspensions;
Part 44: Plastic tips for pipettes-pipettes PVC.

Рок

Рокот за прием на понудите беше 2018-09-03. Набавката беше објавена на 2018-07-24.

Кој? Што?
Историја на набавките
Датум Документ
2018-07-24 Оглас за договор
Оглас за договор (2018-07-24)
Предмет
Опсег на набавката
Наслов: Blood-testing reagents
Количина или опсег:
“39 880 000,00”
Вкупна вредност на набавката: 39 880 000,00 💰
Метаподатоци на огласот
Оригинален јазик: англиски 🗣️
Вид на документ: Оглас за договор
Природа на договорот: Стоки
Регулатива: Друго
Заеднички речник на набавки (CPV)
Шифра: Реагенси за тестирање крв 📦

Постапка
Вид на постапка: Отворена постапка
Вид на понуда: Поднесување за еден или повеќе делови
Критериуми за доделување
Најниска цена

Договорен орган
Идентитет
Земја: Северна Македонија 🇲🇰
Вид на органот кој доделува: Друго
Име на органот кој доделува: Institute of Transfusion Medicine
Поштенска адреса: Vodnjanska 17
Поштенски број: 1000
Поштенско место: Skopje
Контакт
Е-пошта: transfuziologija@gmail.com 📧
Телефон: +38 923226923 📞
Факс: +38 923119227 📠

Референца
Датуми
Датум на испраќање: 2018-07-24 📅
Рок за поднесување: 2018-09-03 📅
Датум на објавување: 2018-07-26 📅
Идентификатори
Број на огласот: 2018/S 142-325909
OJ-S издание: 142
Извор: OJS 2018/S 142-325909 (2018-07-24)